 NEW YORK and VIENNA, Austria, Sept. 15, 2021 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced it has entered into a clinical collaboration and supply agreement with Merck Co., Inc., Kenilworth, NJ., USA known as MSD outside of the United States and Canada to evaluate the combination of HB-200, a novel arenaviral immunotherapeutic, and Merck Co., Inc., Kenilworth, NJ., USAs anti-PD-1 therapy, KEYTRUDA pembrolizumab as first-line treatment for patients with advanced head and neck squamous cell carcinoma HNSCC. 